You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體-B(03681.HK):治療類風濕關節炎的SM03 II期臨牀研究報告摘要已獲接受在2020年歐洲風濕病學大會上作口頭陳述
格隆匯 04-07 22:27

格隆匯4月7日丨中國抗體-B(03681.HK)宣佈,有關公司的旗艦產品SM03獲得歐洲抗風濕病聯盟("EULAR",一個代表歐洲所有國家的關節炎 /風濕病人羣、健康專家及風濕病科學協會的廣泛認可的組織)的認可的最新進展。

於2020年3月30日,EULAR 的科學計劃委員會(Scientific Programme Committee)知會公司,公司早前遞交的摘要已獲接受在2020年歐洲風濕病學大會(EULAR Congress 2020)("大會")上作口頭陳述,該大會現時計劃於2020年6月3日舉行。公司於2020年1月21日向EULAR遞交關於治療類風濕關節炎的SM03 II期臨牀研究報告摘要,題為"重組抗人CD22單克隆抗體SM03對中國類風濕關節炎患者的療效及安全性:II期隨機雙盲多劑量安慰劑對照研究"("摘要"),其檢測SM03在治療中度至重度類風濕關節炎患者時的安全性及臨牀療效。治療類風濕關節炎的SM03 II期臨牀研究的主要研究者張奉春教授將發表陳述,該陳述為研究與開發SM03的一部分。據公司所知,此乃首次向科學界公開使用抗CD22抗體治療類風濕關節炎的II期臨牀報告,董事認為,這是摘要獲接受於大會上口頭陳述的其中一個主要原因,表明公司研究結果的重要性獲得國際認可。據公司所知,公司為少數幾家獲邀在大會上發表口頭陳述的中國生物科技公司之一。此外,該摘要將於EULAR的電子《摘要集》(一本EULAR的官方期刊《風濕病年鑑(ARD)》的官方增刊)上發佈。

公司的旗艦產品SM03為全球同類靶點中首個治療類風濕關節炎潛在的單抗藥物,對其他免疫性疾病亦具有潛在療效,目前在中國進行III期臨牀試驗,預期將於2021年年底商業化。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account